Drugs Made In America Acq... (DMII)
NasdaqGM: DMII
· Echtzeitkurs · USD
10.13
+0.00 (0.00%)
Zum Schluss: Aug 12, 2026, 1:20 PM
Drugs Made In America Acquisition II Corp. (DMII) Stock Price, Analysis & Data
0.00% (1D)
| Geld | 10.11 |
| Marktkapitalisierung | 645.28 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | 8.58 Mio |
| Beta | n/a |
| EPS (ttm) | 0.13 |
| KGV (TTM) | 77.92 |
| Forward-KGV | n/a |
| KBV (TTM) | -36.18 |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | 10.09 |
| Volumen | 25 |
| Ø Vol. (20D) | 66,100 |
| Eröffnung | 10.13 |
| Vortagesschluss | 10.13 |
| Tagesspanne | 10.13 - 10.13 |
| 52-Wk Range | 9.86 - 10.20 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über DMII
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York...
Branche Shell Companies
Sektor Financial Services
IPO Datum Dec 3, 2025
Mitarbeiter n/a
Börse NasdaqGM
Tickersymbol DMII
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Drugs Made In America Acquisition II 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (n/a). Der Gewinn lag bei 4.19 Mio, ein Anstieg von undefined %.
Finanzberichte
